0001477932-26-003228
SEC filingQ1 losses narrowed significantly to -$315.8K from -$1.5M year-over-year, driven by sharp operating expense reductions amid zero revenue, as resources prioritize FDA PMA for CelluSTAT, easing cash burn but sustaining liquidity challenges.
United Health Products maintained its zero-revenue profile in Q1 2026, reporting $0 in sales identical to Q1 2025, as the Company continues directing all capital and resources toward securing a Class III PMA for its CelluSTAT hemostatic technology. This strategic choice prioritizes regulatory approval over near-term commercialization, positioning the business for potential market entry in intestinal and thoracic procedures once cleared, but prolonging cash consumption in the interim.
Progress toward PMA includes an expected GCP audit completion by end-July 2026, while the Company funds these efforts without revenue generation. This focus sustains operational discipline but heightens dependence on external capital, with PMA success critical to transitioning from losses to potential scalability.